Millennium has a number of product candidates being evaluated for their potential roles in treating various forms of cancer:
|
|
VELCADE® (bortezomib) for Injection is being investigated in additional clinical settings.
|
|
|
MLN518 is a small molecule specifically designed to inhibit the FLT-3 receptor tyrosine kinase (RTK) in patients with acute myeloid leukemia (AML). MLN518 is in Phase I/II clinical testing in patients with AML.
|
|
|
MLN8054 is a novel small molecule inhibitor of Aurora kinase(s) and exhibits potent anti-tumor activity against a variety of human tumor xenograft models. MLN8054 is in Phase I studies in patients with advanced solid tumors.
|
|
|
MLN4924 has shown substantial activity in a broad range of preclinical solid and hematological tumor models.
|
|
|
MLN2238 in pre-clinical models, showed superior efficacy relative to VELCADE with potential in a broader set of hematological and solid tumors.
|
Rigorous clinical trials will be necessary to determine the ultimate clinical benefits of these compounds.
